AmeriCare Home Health has been acquired by Brooks Rehabilitation
The private shareholders of AmeriCare Home Health (AmeriCare) have sold the company to Brooks Rehabilitation. Financial details have not been disclosed.
AmeriCare is a leading provider of home healthcare services including skilled nursing, physical therapy, occupational therapy, speech therapy, social work, home health aide, and private duty. The company is headquartered in Jacksonville, Florida, and operates 10 satellite office locations serving 23 counties in northeast and central Florida.
Brooks Rehabilitation is a recognized leader in providing a system of world class rehabilitation services. It operates an inpatient hospital providing rehabilitation and medical care for people requiring intensive inpatient therapy, 26 outpatient clinics, as well as Brooks Home Care which serves northeast Florida.
Oaklins' team in Jacksonville acted as financial advisor and intermediary to the seller in this transaction.
Talk to the deal team
Related deals
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Learn morebioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Learn moreSLT has been acquired by Indutrade
SLT S.r.l. has been acquired by Indutrade AB and will be integrated into the group’s life science business area. The transaction is Indutrade’s fifth acquisition in 2025 and is expected to have a marginally positive impact on the group’s earnings per share.
Learn more